BioCentury | Jan 22, 2021
Product Development

Slaoui on Warp Speed’s successes, limitations and lessons

...of doses, getting them into people’s arms, is another story. Why has it been so bad...
BioCentury | Jan 20, 2021
Politics, Policy & Law

Exit interview: Hahn departs after tumultuous tenure, advocating greater independence for FDA

...reckless, incompetent and uncaring President, some really bad...
BioCentury | Jan 12, 2021
Product Development

Lilly’s amyloid therapy not a big step forward from Biogen’s

...the idea that soluble oligomers are the bad...
BioCentury | Jan 9, 2021
Product Development

Possible factors behind Sarepta’s DMD miss

...but instead, “appears to relate to improbable bad...
BioCentury | Jan 1, 2021

The good, the bad and the COVID: BioCentury’s playlist for pandemic times

Saying goodbye to a grueling year, BioCentury editors have furrowed among the disasters to pick out some of the positives from 2020, and call out some of the worst of the pandemic’s collateral damage....
BioCentury | Dec 31, 2020
Product Development

Stoffels on how J&J designed its COVID-19 vaccine for maximum impact: a BioCentury audio interview time, and avoid this type of suffering for the world? Because it's a very bad...
BioCentury | Dec 30, 2020
Product Development

2020’s silver linings, New Year’s hopes: a BioCentury podcast

...Jeff Cranmer: So let's get to the bad...
...with how much regulation is good or bad...
...I don't know that it was as bad...
BioCentury | Dec 18, 2020
Product Development

2021 Predictions: a BioCentury survey

...targets,” wrote one respondent. “At least one bad...
BioCentury | Dec 10, 2020

Late in a year of cancer deals, Gilead spends $1B+ to add an antiviral for HDV

...included Maxwell Biotech Venture Fund and High-Tech Gründerfonds. Founded in 2011, the company is based in Bad...
BioCentury | Dec 8, 2020
Product Development

ASH Monday, Biden’s picks & vaccine conundrums: a BioCentury podcast

...they take them just by chance some bad...
Items per page:
1 - 10 of 1099